Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Mears H1 profit seen 'modestly ahead' of expectations

(Sharecast News) - Mears Group said on Tuesday that first-half profits are set to be "modestly ahead" of the prior year and consensus expectations following strong trading. Given the "positive trends" seen in the first half, the company - which provides services to the UK housing sector - now expects revenues and adjusted pre-tax profit of not less than £1.06bn and £54m, respectively. Consensus expectations are for £1.06bn and £50.9m, respectively.

Mears pointed to solid growth in its maintenance-led activities in the first half, driven by regulatory market drivers increasing spend from the group's registered provider clients and further underpinned by the 100% contract retention reported over the last 12 months.

As expected, management-led activities have continued to normalise as asylum related contingent solutions are replaced with long-term residential accommodation, it said. "This transition continues to be managed well," Mears added.

The company said operating margins have continued to strengthen and profits have again been underpinned by strong operating cash flows.

Chief executive Lucas Critchley said: "Trading in the first half has been excellent across the group.

"We have continued to make progress against each of our key strategic goals; delivering growth in maintenance activities, developing a full compliance and asset management offer, and positioning the group to deliver additional housing services to Central Government."

At 1000 BST, the shares were up 2.8% at 398.50p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.